Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

CONTEXT: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. OBJECTIVE: Our objective was to demonstrate th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C.-C., Gadelha, M., Fleseriu, M., van der Lely, A. J., Farrall, A. J., Hermosillo Reséndiz, K., Ruffin, M., Chen, Y., Sheppard, M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Endocrine Society 2014
Aiheet:
Endocrine Care
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3965714/
https://ncbi.nlm.nih.gov/pubmed/24423324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2013-2480
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia